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ABSTRACT
Introduction: Delayed-release dimethyl fuma-
rate (DMF) is an effective treatment for multiple
sclerosis (MS). Some patients experience gas-
trointestinal (GI) adverse events (AEs) that may
lead to premature DMF discontinuation. This
study characterized the impact of site-specific
GI management strategies on the occurrence of
GI events and discontinuation patterns.
Methods: Data on GI events and DMF persis-
tence were retrospectively abstracted from
medical records of patients treated with DMF in
routine medical practice in the EFFECT study
(NCT02776072). GI management strategies
were assessed via a study site questionnaire.
Discontinuation rates were analyzed according
to counseling patterns.
Results: Of 826 DMF-treated patients at 66
sites, 809 from 65 sites were eligible for the GI
analysis; of these, 27% experienced GI AEs.
Within 1 year of treatment, 14% (118/826) of
patients discontinued DMF, 5% (44/809) due to
GI events. Most sites (92%) reported that
patients were very likely ([75% of the time) to
be counseled about GI events at/before DMF
treatment initiation and/or to be recommended
that DMF be taken with food (86%); 48% of sites
reported to be very likely to recommend using
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symptomatic therapies for GI AEs. Lower dis-
continuation rates were reported at sites very
likely versus not very likely (B 75% of the time)
to (1) provide counseling; (2) provide specific
details regarding GI events; or (3) recommend
taking DMF with food, and/or using symp-
tomatic GI therapies.
Conclusion: Counseling and other GI manage-
ment strategies at initiation of DMF treatment
appear to reduce the burden of GI events, and a
variety of GI management strategies may
improve DMF persistence.
Trial Registration: NCT02776072.
Funding: Biogen (Cambridge, MA, USA).
Keywords: Gastrointestinal events; Multiple
sclerosis; Retrospective study; Tecfidera
INTRODUCTION
Delayed-release dimethyl fumarate (DMF) is an
oral treatment option for patients with relaps-
ing–remitting multiple sclerosis (RRMS). Upon
oral administration, DMF is rapidly converted to
its active metabolite monomethyl fumarate [1],
which is then widely distributed throughout the
body [2, 3]. DMF has demonstrated significant
and sustained therapeutic efficacy across a range
of clinical and radiologic measures in phase 3
clinical trials and in a long-term extension study,
ENDORSE [4–6]. The overall safety and tolera-
bility profile of DMF is favorable, although
patients often experience gastrointestinal (GI)
adverse events (AEs), such as diarrhea, nausea,
abdominal pain, vomiting, and dyspepsia [7].
Clinical trials and community-based real-world
studies have indicated that GI tolerability issues,
if experienced, occur most frequently within the
first 10–12 weeks of DMF treatment initiation,
with the incidence decreasing over time. Thus, it
is important that counseling patients regarding
potential GI AEs occurs at or before treatment
initiation [4, 6–10]. Although most treatment-
emergent GI AEs are generally mild or moderate
in nature [11], these events may lead to poor
treatment compliance or premature DMF dis-
continuation for some patients.
In a pooled analysis of patients who received
placebo (n = 771) or DMF 240 mg twice daily
(n = 769) in the 2-year, randomized, double-
blind, placebo-controlled phase 3 DEFINE and
CONFIRM clinical trials, 31–40% of patients
reported GI AEs, with\1–3% of patients discon-
tinuing DMF due to these events [7]. However, a
multicenter, open-label, single-arm study (MAN-
AGE) and other real-world, practice-based studies
have reporteddiscontinuation ratesof10–29%for
all AEs and 7–14% for GI-specific AEs [8, 12, 13].
As of July 31, 2018,[ 340,000 patients have
received DMF treatment, represent-
ing[ 625,000 patient-years of exposure [14].
Therefore, real-world DMF data can offer
important, potentially more generalizable,
insights into management strategies for GI AEs.
In order to capture the levels and types of con-
sensus on best practice management strategies
from DMF prescribers, a Delphi study was con-
ducted among North American clinicians [10].
Clinicians completed two rounds of question-
naires developed by a steering committee; con-
sensus in round 2 was considered to be attained
if C 70% of respondents agreed on a particular
strategy. The Delphi consensus on effective GI
management strategies, as well as a preliminary
report suggesting that individual patient
coaching leads to decreased avoidable therapy
discontinuation due to GI AEs [10, 15], was
utilized to guide this research [10].
The EFFECT study (NCT02776072) was
undertaken to evaluate the comparative effec-
tiveness of DMF in patients with RRMS in both a
clinical practice setting and in a subset of newly
diagnosed patients. As part of the EFFECT study,
a GI analysis was designed to further investigate
(1) the strategies to manage and mitigate DMF-
associated GI events in the real-world setting
and (2) the type of GI AEs occurring in a real-
world setting, GI AEs leading to treatment dis-
continuation, and the frequency of GI event
management strategies used in patients treated
with DMF [16].
METHODS
Study Design and Patients
The EFFECT study was a global, multicenter,
medical chart abstraction study in patients with
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RRMS treated with select disease-modifying
therapies [DMTs; i.e., DMF, glatiramer acetate
(GA), teriflunomide, or fingolimod] according
to routine clinical practice [Electronic Supple-
mentary Material (ESM) Fig. S1]. Key patient
inclusion criteria were written informed con-
sent; age C 18 years; diagnosis of RRMS per
2010 McDonald criteria [17]; DMF treatment
initiation after January 2011 with C 12 months
of follow-up data available following DMF ini-
tiation; treatment naive or have had only one
prior DMT [interferon (IFN) or GA]; and multi-
ple sclerosis relapse history for up to 3 years.
Patients were included irrespective of total time
on treatment. Key exclusion criteria were diag-
nosis of a progressive form of MS before or
during data collection; prior treatment with a
DMT other than IFN or GA; treatment with any
formulations of DMF or compounded fumarates
prior to DMF treatment initiation; and concur-
rent enrollment in any interventional clinical
trial of an investigational product during the
time of medical chart abstraction.
The GI analysis was conducted at sites that
abstracted data from patients receiving DMF
treatment. Sites were selected based on feasi-
bility assessment of willingness and capability
for participation in the study. Factors such as
approximate number of patients treated with
MS therapies, site start-up timelines, ability to
retrospectively identify eligible medical records,
and resources available for chart abstraction
were considered. Chart abstraction occurred
from May 2016 through January 2017.
Medical charts were reviewed at a single time
point, and patient information was captured
and managed by study sites on web-based elec-
tronic case report forms. Data were collected for
patients receiving DMF for selected GI AEs and
included type of event, date of onset, duration
of event, concomitant treatment received, and
any interruption, dose reduction, or discontin-
uation of DMF treatment. Physicians or their
designees completed a structured, site-level
questionnaire to report the likelihood of exe-
cuting strategies for mitigating and/or manag-
ing GI events that may be experienced by DMF-
treated patients. Responses from the question-
naire were collected to evaluate GI management
practices (ESM Fig. S1) using the scale described
below and were reported in the aggregate as
frequencies.
Outcomes
The GI analysis endpoints were the proportion
of DMF discontinuations related to selected GI
events overall, by site, and by patient demo-
graphics, as well as the frequency of each strat-
egy used for mitigating and managing GI
events. A post hoc analysis assessed GI events
and discontinuation rates according to survey
responses to evaluate the impact of counseling
on clinical outcomes.
Questionnaire to Evaluate GI Management
Practices
The structured questionnaire for evaluating GI
management practices consisted of a total of 26
items assessing the site characteristics, respon-
dent type (e.g., neurologist, nurse practitioner),
resources used for counseling, counseling habits
(as outlined in the questionnaire, see ESM
Appendix S1), and GI AE mitigation techniques.
The questionnaire was built to assess the likeli-
hood that sites were utilizing the techniques
recommended by physicians using the Delphi
consensus methodology to manage or mitigate
GI events with DMF [10]. The questionnaire was
developed in collaboration with physician and
nurse healthcare providers (HCPs) and was
piloted in a separate group of HCPs to assess for
clarity and comprehension of the individual
questions and to assess the duration of time
required to complete the questionnaire.
Each site completed one questionnaire,
responding to as many questions as possible.
Sites were asked to describe their practice cen-
ter, including size, type, and available staff. Sites
also indicated the likelihood of various GI
management and counseling strategies using a
scale as follows:
• Not very likely (B 75%)
– Never (0%)
– Unlikely ([0–25%)
– Somewhat likely ([25–75%)
• Very likely ([75%)
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Statistical Analysis
All analyses were performed using SAS version
9.2 or higher (SAS Institute, Cary, NC, USA).
Descriptive analyses corresponding to the specific
research objectives were performed to characterize
the GI analysis population. Continuous variables
are reportedasnumberof patients,mean, standard
deviation (SD),median,minimum,andmaximum
where appropriate. Categorical variables are sum-
marized as number of patients and percentage.
Data were summarized for (1) select GI
events and GI events leading to DMF discon-
tinuation overall and over time, (2) each GI
management strategy as reported in the GI
questionnaire, and (3) the site-level discontin-
uation rates according to counseling patterns.
Standard Protocol Approvals,
Registrations, and Patient Consent
The protocol was approved by the relevant
Institutional Review Board for each study site. All
procedures performed in studies involving
human participants were in accordance with the
ethical standards of the institutional and/or
national research committee and with the 1964
Helsinki declaration and its later amendments or
comparable ethical standards. Informed consent
was obtained from all individual participants
included in the study. The study was conducted
in accordance with the Declaration of Helsinki,
International Conference on Harmonization—
Good Clinical Practice, and all applicable laws
and regulations. A waiver of informed consent,
based on non-personally identifiable retrospec-
tive data collection and minimal risk, was at the
discretion of the individual Institutional Review
Boards or Ethics Committees for each site. When
required, participants provided written informed
consent before study enrollment.
RESULTS
Patients and Sites
Overall, 826 DMF-treated patients were enrolled
at 66 sites (Table 1), with patient recruitment
per site ranging from 1 to 107 patients (median
7). Mean (SD) age was 44 (12) years; 76% (624/
826) of patients were female; 57% (467/826) of
patients were from the USA (Region 1); and 32%
(265/826) were treatment naive. Of the patients
with a prior MS treatment, 76% (393/515) had
received IFN beta. A total of 14% (118/826) of
patients discontinued treatment with DMF,
most commonly due to tolerability issues [9%
(71/826 patients)].
GI Analysis
A total of 809 patients from 65 sites who com-
pleted the GI questionnaire were included in
the GI analysis. In the first 12 months of treat-
ment, 27% (216) of patients had at least one GI
event recorded in their medical charts. The
most commonly reported GI events were nausea
[11% (87 patients)], diarrhea [9% (74)],
abdominal pain [6% (51)], vomiting [5% (43)],
upper abdominal pain [2% (20)], abdominal
discomfort [2% (19)], and dyspepsia [2% (15)].
The majority (81%) of GI events occurred
within the first 5 weeks of DMF treatment ini-
tiation (Fig. 1). However, only 5% (44 patients)
discontinued DMF due to GI events, with nau-
sea [3% (21)] being the most common event
leading to discontinuation, followed by diar-
rhea [2% (19)], abdominal pain [2% (15)], and
vomiting [2% (13)]. Similar to the onset of GI
events, the majority of events leading to dis-
continuation occurred in the first 5 weeks of
therapy (92%).
Titration schedules were recorded in the
medical charts for 727/809 patients; data were
missing for 82 patients. Approximately 50%
(331/727) of patients titrated their DMF dose for
1 week, 20% (151/727) titrated it for 2–4 weeks,
and\ 10% (59/727) titrated it for[4 weeks. No
pattern of discontinuation was identified when
the data were stratified by titration schedule.
However, the number of patients with no
titration schedule reported in their medical
records (186/727) or with missing data impac-
ted the evaluable sample size and the ability to
interpret the data. Similarly, of the 216 patients
with C 1 GI event, only 4% received dosage
modification and 11% received symptomatic
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therapy. Therefore, it was not possible to per-
form additional analyses due to the small
number of evaluable patients.
Discontinuation rates due to GI events var-
ied by region. Regions were defined on the basis
of geography, as well as by type of healthcare
system and access to health care in each coun-
try. Discontinuation rates were 7.1% (32/451) in
Region 1 (USA), 3.4% (11/320) in Region 2 (Ar-
gentina, Australia, Canada, France, Germany,
Italy, Spain, Switzerland, UK), and 2.6% (1/38)
in Region 3 (Croatia, Czech Republic, Hungary).
Patient Management Strategies:
Questionnaire Results
Respondent and Site Characteristics
Questionnaire respondents were physicians
(48%), registered nurses (15%), nurse practi-
tioners (14%), physician assistants (2%), and
other (22%; included clinical research coordi-
nators, research assistants, and study coordina-
tors). Respondents characterized their site type
as nonhospital-based community practice
(45%), hospital-based community practice
(28%), academic setting (18%), or other (9%).
They characterized their practice size as B 250
patients (25%), 251–500 patients (14%),
501–1000 patients (26%), or[ 1000 patients
(35%).
Site-Reported GI Management and Mitigation
Practices
Most sites [86% (54/63)] were very likely to
recommend that DMF be taken with food or
that specific diets be followed, such as high fat,
high protein, or high starch (Fig. 2a). Addi-
tionally, 48% (30/62) of sites were very likely to
recommend the use of symptomatic therapies
for GI AEs. The most frequently recommended
symptomatic therapies included proton pump
inhibitors, secretion blockers, and antidiarrheal
medications (Fig. 2b).
Site-Reported Counseling Practices
Most sites [92% (58/63)] reported that patients
were very likely to be counseled orally regarding
GI events at or before the initiation of DMF
Table 1 Baseline characteristics and patient disposition
Characteristic DMF-treated patients
(n = 826)
Age, median (min, max), years 44 (18, 73)
Age, mean (SD), years 44 (12)
Female 624 (76)
Regiona
Region 1 467 (57)
Region 2 320 (39)
Region 3 39 (5)
Any prior MS treatmentb 515 (63)
IFN beta 393 (48)
GA 115 (14)
Otherc 7 (\ 1)
Treatment naive 265 (32)
Reasons for discontinuing prior MS treatmentb,d,e
Tolerability 244 (30)
Efﬁcacy 165 (20)
Adverse events 14 (2)
Patient preference 130 (16)
Other 53 (6)
Discontinued DMF by 1 year,
n (%)
118 (14)
Reasons for discontinuing DMFd
Tolerability 71 (9)
Efﬁcacy 19 (2)
Safety 16 (2)
Patient preference 14 (2)
Other 11 (1)
Values in table are presented as a number with the percentage in
parenthesis, unless noted otherwise
DMF delayed-release dimethyl fumarate, GA glatiramer acetate,
IFN interferon, max maximum, min minimum, MS multiple
sclerosis
a Region 1: USA; Region 2: Argentina, Australia, Canada,
France, Germany, Italy, Spain, Switzerland, UK; Region 3:
Croatia, Czech Republic, Hungary
b Based on 816 patients with data available
c Five patients previously used a chronic MS steroid, one patient
received natalizumab, and one patient received rituximab
d More than one reason for discontinuing prior MS treatment
was permitted; data were collected retrospectively
e Reasons for discontinuation were based on clinical judgement;
no formal criteria were provided
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treatment (Fig. 3), and 34% (22/64) of sites were
very likely to utilize a member of the healthcare
team, in addition to the prescriber, to counsel
patients at or before DMF treatment initiation
(Fig. 3). In the event the prescriber was unavail-
able to provide counseling at or before DMF
treatment initiation, 19% (12/63) of sites were
very likely to utilize another member of the
healthcare team to counsel patients. The other
HCPs providing counseling included registered
nurses, physicians other than the prescribing
physician, nurse practitioners, and physician
assistants. Most sites [83% (52/63)] were very
likely to provide patients with specific details of
GI events (timing of onset, incidence, severity,
and duration); 44% (28/64) of sites were very
likely toprovidepatientswith information about
GI events in written form (handwritten, printed,
Fig. 1 Incidence of gastrointestinal (GI) adverse events (AEs) over time. The numbers above bars are the proportion (in
percentage) of patients with GI AEs. DMF Delayed-release dimethyl fumarate
Fig. 2 Most commonly recommended types of foods
(a) and classes of medication(s) (b) for GI event
mitigation. Sites were instructed to select all that applied.
n Number of sites (total number of sites 65). aOther
classiﬁcation included antacid medications (e.g., calcium
carbonate) (n = 22); histamine 2 blocker (n = 1), and
nonsteroidal anti-inﬂammatory drugs (n = 1)
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emailed, and online), and 92% (59/64) of sites
instructed patients to contact the office if they
experienced GI events. Seventy-eight percent
(49/63) of sites were very likely to advise patients
to titrate the dose of DMF over the first week of
treatment to prevent GI events, but only 41%
(26/63) of sites were likely to advise patients to
temporarily reduce the dose ofDMF if the patient
experienced GI events; only 26% (14/53) of sites
were very likely to advise patients to temporarily
reduce the dose of DMF to 120 mg twice daily, as
per approved package labeling, if they experi-
enced GI events; and only 13% (8/63) of sites
were very likely to advise patients to temporarily
interrupt the dose of DMF. Most sites [86% (54/
63)] were very likely to recommend food as
therapy; 48% (30/62) of sites were likely to rec-
ommend symptomatic therapy. Sites that were
likely to counsel patients orally alsowere likely to
indicate that written information was available
[42% (27/65)], to recommend food [77% (50/
65)], and to recommend concomitant symp-
tomatic therapy [45% (29/65)].
Discontinuation Rates According
to Counseling Patterns: Questionnaire
Results
In a descriptive analysis, lower discontinuation
rates were reported at sites that were very likely,
versus sites that were not very likely, to have a
member of the healthcare team provide coun-
seling in addition to or in lieu of the prescribing
physician, provide specific details about GI
events, recommend taking DMF with food, and/
or use symptomatic GI therapies (Fig. 4). Dis-
continuation rates were similar at sites that
were very likely to provide counseling in the
form of written information versus sites that
were not very likely to do so (Fig. 4). The sites
that utilized written information in their
handouts included GI management strategies
identified in the Delphi study (ESM Appendices
S2 and S3).
DISCUSSION
In this GI analysis of DMF-treated patients, the
majority of GI AEs and GI-related discontinua-
tions in this study occurred within the first
month of treatment initiation, stressing the
importance of preparing the patient for possible
DMF-related GI events and the need for early
intervention. Similarly to the single-arm studies
MANAGE and TOLERATE, the incidence of GI
events was highest in the first month of DMF
treatment [8, 18]. Unfortunately, due to the
retrospective nature of this study, based on data
collection via chart abstraction, we were not
able to determine the prevalence or duration of
Fig. 3 Counseling practices regarding GI event associated
with DMF treatment, reported by sites. Very likely
indicates counseling for[ 75% of the time. Not all sites
responded to all questions [n = 63 for counseled; n = 64
for counseled by another healthcare provider (HCP) in
addition to the prescriber; n = 63 for counseled by
another HCP, in lieu of the prescriber]. aAnother HCP
in addition to the prescriber could include a registered
nurse, physician, nurse practitioner, physician assistant, or
pharmacist. bHCP in lieu of the prescriber could include a
registered nurse, physician, nurse practitioner, physician
assistant, or pharmacist
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AEs because recurrent events may not have been
captured and AE ‘‘stop dates’’ are frequently not
reported in medical charts or listed as unknown.
A future prospective clinical trial in which
prevalence and duration of AEs are analyzed
would be informative.
The incidence of GI AEs (27%) and the pro-
portion of patients discontinuing treatment as a
result of GI AEs (5%) in our analysis was some-
what lower than has been reported in other real-
world studies, but similar to what was observed
in controlled clinical trials [4, 6, 11]. The data
from the site survey responses indicate a high
likelihood that the patients in this study were
counseled about GI symptoms associated with
DMF treatment. It is hypothesized that the
implementation of GI management and miti-
gation strategies mimics the clinical trial expe-
rience for the patient and is improving as
experience in the use of DMF increases. DMF
was approved for use by the US Food and Drug
Administration in March 2013, followed by the
European Medicines Agency in January 2014.
Thus, of the patient charts abstracted for this
study, more patients initiated DMF during the
period 2014–2015 [65% (528/809)] versus pre-
vious years [35% (281/809)]. There were fewer
discontinuations due to GI AEs among patients
initiating DMF treatment in the latter half of
the recruitment period versus the initial half of
the recruitment period [4.2% (22/528) vs. 7.8%
(22/281)], which supports the hypothesis that
experience with DMF is resulting in improved
practice management over time. Another
explanation for the lower number of discon-
tinuations due to GI AEs in our analysis com-
pared to those reported in other real-world
analyses [8, 12, 13], which may also relate to the
timing of DMF initiation, is that the majority of
patients enrolled in this study initiated therapy
during the latter half of the study when pre-
scribers had a better understanding of how to
manage patients with GI events using tools like
the Delphi consensus paper as references [10].
In general, sites that were more likely to fre-
quently utilize these strategies had lower rates
of discontinuation due to GI AEs in this study,
although only discontinuation rates, not
adherence to treatment, were specifically asses-
sed. Overall discontinuation rate was utilized as
a surrogate for adherence to treatment, which
does not necessarily mean the patient received
the full dose; for example, treatment could have
decreased to one dose per day to enable the
Fig. 4 Proportion of patients who discontinued DMF by
site frequency of GI management strategy implementation.
Speciﬁc details of GI event included information on
timing of onset, incidence, severity, and duration. Nonoral
counseling materials included handwritten, printed,
emailed, online, or other information. Sites could select
more than one option. Not all sites responded to all
questions; sites may have been in the very likely and/or not
very likely category for each of the mitigation strategies
depending on their response in the questionnaire. Very
likely,[ 75% of the time; not very likely, 0–75% of the
time. Number of discontinuations/number of patients
who received the management strategy described is shown
in the ﬁgure (proportions are indicated along the X-axis)
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patient to better tolerate the GI effects. Dose
modifications were not measured in this study,
but they are an important variable to assess in
future research. Finally, another inherent limi-
tation of this study, due to its design, is the
possibility of under-reporting of events col-
lected in this study, as the data are reliant upon
accuracy of the medical charts.
Lower discontinuation rates were observed at
sites that were very likely, versus sites that were
not very likely, to have an HCP, in addition to or
in lieu of the prescriber, counseling patients,
providing specific details about GI events, rec-
ommending taking DMF with food, or recom-
mending using symptomatic therapy. Therefore,
providing this type of specific guidance to
patients may be most helpful to reducing dis-
continuations due to GI events. Of note, only a
small percentage of patients were recorded actu-
ally using symptomatic therapy or having a
modified dose titration schedule in the patient-
level chart data. Due to inherent limitations in
the study design, this value may be under-re-
ported because the majority of symptomatic
therapies are over-the-counter therapies or
because dose titration instructions may have
been given verbally to some patients and not
recorded in themedical chart data. Additionally,
this studydidnotdemonstrate thatuseofwritten
information as a counseling strategy was effec-
tive at reducing site-level discontinuation rates.
It is speculated that written counselingmay have
beenoffered insteadof (rather thana supplement
to) oral counseling. Other studies have shown
written forms of counseling may be an effective
part of theDMFGImanagement strategy [15, 19].
The EFFECT study observed varying discon-
tinuation rates among the different regions.
Potential reasons for the observed variations in
discontinuation rates include differences in
regional practices of implementing GI man-
agement strategies and variation in years of
experience in prescribing DMF. As part of a post
hoc analysis, it was observed that the incidence
of GI adverse events in Region 1 [29% (129/
451)] versus combined Region 2/3 [24% (87/
358)] were similar in this study, yet discontin-
uation rates were strikingly different in Region 1
[7% (32/451)] versus combined Region 2/3 [3%
(12/358)]. Consistent with the analysis for the
entire population, similar patterns of lower
discontinuation rates for patients initiating
therapy in more recent years were also observed
when stratified by region. One hypothesis for
the difference in discontinuation rates despite a
similar incidence of AEs is that the management
and mitigation strategies implemented by these
regions drive the differences in discontinua-
tions due to GI AEs associated with DMF treat-
ment. Another hypothesis is that limited access
to a wider range of MS treatment alternatives in
particular countries may result in lower dis-
continuation rates irrespective of side effects.
Other inherent country differences that may
influence patient tolerability to DMF and will-
ingness to tolerate side effects, such as diet,
availability of over-the-counter symptomatic
therapies, exercise, meal timing, and cultural
norms that discourage the reporting of side
effects, should be noted as well, as supported by
other real-world studies from several countries
that have reported differences in overall and GI-
related discontinuation rates [12, 13, 18, 20].
In summary, DMF is efficacious for the treat-
ment of RRMS, and oral administration is a con-
venient dosing form for patients. However, for
patients to optimize the efficacy benefits of DMF
they must overcome potential initial tolerability
hurdles, including DMF-related GI AEs. GI
counseling and management strategies imple-
mented early in the treatment course may be
critically important in driving patients to reach
this goal.
CONCLUSIONS
The results of this study suggest that the use of a
variety of GI counseling and management
strategies may improve persistence on DMF
therapy and increase the likelihood that
patients can optimize the efficacy benefits of
long-term DMF treatment.
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